WASHINGTON — Until Tuesday, nearly every single Democratic primary debate has focused on the same health care issue: “Medicare for All.”
So when Democrats got the chance to talk about their plans to lower drug prices, they jumped. Candidates uniformly criticized drug companies as examples of corporate irresponsibility and outsize political influence.
Sen. Elizabeth Warren (D-Mass.), in particular, doubled down on a pledge to lower drug prices on her first day as president, using executive action to make it easier for generic drug makers to move in on brand-name drugs that were created using federally funded research.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect